Head-To-Head Review: LeMaitre Vascular (LMAT) vs. Glaukos (NYSE:GKOS)

LeMaitre Vascular (NASDAQ: LMAT) and Glaukos (NYSE:GKOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Risk and Volatility

LeMaitre Vascular has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Profitability

This table compares LeMaitre Vascular and Glaukos’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LeMaitre Vascular 21.09% 19.49% 17.06%
Glaukos -3.49% -4.11% -3.54%

Dividends

LeMaitre Vascular pays an annual dividend of $0.28 per share and has a dividend yield of 0.8%. Glaukos does not pay a dividend. LeMaitre Vascular pays out 32.6% of its earnings in the form of a dividend. LeMaitre Vascular has increased its dividend for 2 consecutive years.

Analyst Ratings

This is a breakdown of current recommendations and price targets for LeMaitre Vascular and Glaukos, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LeMaitre Vascular 0 3 3 0 2.50
Glaukos 0 3 5 0 2.63

LeMaitre Vascular currently has a consensus price target of $37.67, indicating a potential upside of 2.97%. Glaukos has a consensus price target of $40.83, indicating a potential downside of 2.66%. Given LeMaitre Vascular’s higher possible upside, analysts clearly believe LeMaitre Vascular is more favorable than Glaukos.

Earnings and Valuation

This table compares LeMaitre Vascular and Glaukos’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LeMaitre Vascular $100.87 million 7.00 $17.17 million $0.86 42.53
Glaukos $159.25 million 9.20 -$90,000.00 N/A N/A

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos.

Insider and Institutional Ownership

73.5% of LeMaitre Vascular shares are owned by institutional investors. 20.3% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 11.6% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

LeMaitre Vascular beats Glaukos on 9 of the 16 factors compared between the two stocks.

About LeMaitre Vascular

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply